RE:RE:RE:RE:RE:Do you see Similarities????
No crystal ball but I had something called Bioexx and held on, through all the lack of news, occasional glimmers of hope; eventually lost $90,000 selling at .01. Lots of posters, including one I've seen here, fared even worse.
Major similarities are: small company with basically a single idea, the greatest asset being a patent for IP in a narrow field, lots of unexplained missed deadlines, near-total lack of info from the mgmt who continue to pay themselves as such.
The advantage MBI has is an interested, and financially supportive, big brother. However, mgmt keeps stalling with no word on the real nature of delays, the power to hurry things along lies with Precision or the CLIA/lab approval process, or some outside agency that doesn't answer to the shareholders of MBI.
With Bioexx it was waiting for approval of canola protein isolate as being safe for human consumption while the company borrowed cash to pay the mgmt. Patent in USA, and EU approval, came after the company welt belly up. CEO got paid until the bitter end.
I know I'm not as well informed on the present status of MBI as most of you , but back when it was .12/share this looked too much like a movie I'd seen before so I bailed.
Thing I like about mining juniors is, once they prove a decent discovery (FCU, CCE, CLQ) sooner or later the value of their commodity rises and the company either sells to benefit themselves and SHs, or goes into production. They may not be a 10-bagger, but the ones with a proven asset eventually go on to make $ for the SHs. Caveat: only applies to North American assets; other jurisdictions too risky.
I still hope MBI turns out well for you all, but your CEO needs to give you info. Good luck.